Comparing the current results to its competitors, Celldex Therapeutics Inc reported Revenue decrease in the 1 quarter 2026 year on year by -97.84 %, despite the revenue increase by the most of its competitors of 14.1 %, recorded in the same quarter.
Celldex Therapeutics inc , slower than the average decrease reported by the company's competitors of -20.94 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -20.94 %
July 29, 2024
Exploring the Promising Efficacy of Barzolvolimab: A Potential Game-Changer in Chronic Inducible Urticaria and Prurigo Nodularis Treatment Options In a noteworthy advancement for the management of chronic skin conditions, Celldex Therapeutics, Inc. (NASDAQ: CLDX) has unveiled a series of promising topline results from its Phase 2 clinical trials investigating barzolvolimab, a humanized monoclonal antibody designed to inhibit the receptor tyrosine kinase KIT. This major step forward particularly affects patients afflicted by chronic inducible urticaria (CIndU), which includes cold urticaria (ColdU) and symptomatic dermographism (SD), as well as prurigo nodularis (PN). Harnessing the Power of BarzolvolimabBarz...
July 16, 2024
Chronic Spontaneous Urticaria (CSU) is a debilitating and chronic skin disorder characterized by the sudden emergence of itchy hives, swelling, and other symptoms that last for six weeks or more. It affects millions of individuals worldwide, significantly impairing their quality of life. The recurrence of symptoms and limited treatment options make CSU a challenging condition to manage.In recent years, the medical community has witnessed significant progress in understanding CSU and developing effective therapies. Celldex Therapeutics has taken a crucial step forward by initiating a global Phase 3 program for their investigational drug, Barzolvolimab. In this article, we will explore the key findings from th...
May 15, 2024
Barzolvolimab Shows Promise in Treatment of Prurigo Nodularis and Chronic Spontaneous UrticariaIn a recent announcement, Celldex Therapeutics, Inc. shared positive updates regarding their experimental drug, barzolvolimab, in the treatment of prurigo nodularis (PN) and chronic spontaneous urticaria (CSU). The company has initiated a Phase 2 study of barzolvolimab for PN, aiming to target mast cells associated with pruritic sensory neurons in PN lesions. Celldex also presented favorable results from a previous Phase 2 study of barzolvolimab in CSU, showing significant improvements in disease activity. These developments bring hope for patients suffering from these chronic and debilitating conditions.Background...
Regeneron Pharmaceuticals Inc operates a business model centered on the discovery and commercialization of cutting-edge biopharmaceuticals, particularly in the fields of ophthalmology, oncology, immunology, and rare diseases. They leverage their strong research and development capabilities, including their proprietary technologies, to create innovative therapies that address unmet medical needs. Additionally, Regeneron forms strategic collaborations and partnerships to enhance their development pipeline and expand market access for their products.
Pfizer Inc operates as a global pharmaceutical company that focuses on researching, developing, manufacturing, and marketing innovative medicines. Its business model emphasizes significant investment in research and development to build a diverse portfolio of therapies across various therapeutic areas, while leveraging strategic alliances and collaborations to enhance commercialization and drive growth.
Oncolytics Biotech Inc operates as a biotechnology company engaged in the development and commercialization of oncolytic viruses as potential therapeutics for the treatment of various cancers. Its business model revolves around identifying and acquiring intellectual property rights, conducting preclinical and clinical studies, and collaborating with pharmaceutical and biotechnology companies for the development and commercialization of its products. The company aims to deliver innovative and targeted cancer therapies to improve patient outcomes globally.
Sources:
Celldex Therapeutics inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Celldex Therapeutics inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
